Buckingham Asset Management LLC continued to hold its position in shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 35,600 shares of the specialty pharmaceutical company’s stock at the end of the second quarter. Buckingham Asset Management LLC owned 0.06% of BioDelivery Sciences International worth $100,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Valley National Advisers Inc. increased its position in BioDelivery Sciences International by 59.0% in the second quarter. Valley National Advisers Inc. now owns 37,715 shares of the specialty pharmaceutical company’s stock valued at $106,000 after buying an additional 14,000 shares during the last quarter. Cutter & CO Brokerage Inc. increased its position in BioDelivery Sciences International by 2.4% in the second quarter. Cutter & CO Brokerage Inc. now owns 43,430 shares of the specialty pharmaceutical company’s stock valued at $122,000 after buying an additional 1,000 shares during the last quarter. NEXT Financial Group Inc increased its position in BioDelivery Sciences International by 9.3% in the second quarter. NEXT Financial Group Inc now owns 47,000 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 4,000 shares during the last quarter. Sterling Investment Management Inc. purchased a new position in BioDelivery Sciences International during the second quarter valued at about $140,000. Finally, Janney Montgomery Scott LLC increased its position in BioDelivery Sciences International by 19.9% in the second quarter. Janney Montgomery Scott LLC now owns 71,800 shares of the specialty pharmaceutical company’s stock valued at $201,000 after buying an additional 11,900 shares during the last quarter. 41.44% of the stock is currently owned by institutional investors and hedge funds.

BioDelivery Sciences International, Inc. (BDSI) opened at 3.10 on Wednesday. The company has a 50 day moving average price of $3.14 and a 200 day moving average price of $2.35. BioDelivery Sciences International, Inc. has a 52-week low of $1.50 and a 52-week high of $3.60. The firm has a market capitalization of $171.97 million, a P/E ratio of 110.71 and a beta of 1.03.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by $0.04. BioDelivery Sciences International had a return on equity of 14.64% and a net margin of 3.34%. The business had revenue of $8.70 million during the quarter, compared to the consensus estimate of $8.45 million. During the same quarter in the previous year, the business posted ($0.31) earnings per share. The company’s quarterly revenue was up 74.0% compared to the same quarter last year. On average, equities analysts forecast that BioDelivery Sciences International, Inc. will post $0.12 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/30/buckingham-asset-management-llc-has-100000-stake-in-biodelivery-sciences-international-inc-bdsi.html.

Several equities analysts recently issued reports on BDSI shares. HC Wainwright set a $4.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a research report on Saturday, June 10th. ValuEngine raised BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Friday, May 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of BioDelivery Sciences International in a research report on Sunday, August 20th. Zacks Investment Research downgraded BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. Finally, Janney Montgomery Scott upped their target price on BioDelivery Sciences International from $3.00 to $4.00 and gave the company a “fair value” rating in a research report on Monday, July 24th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. BioDelivery Sciences International presently has a consensus rating of “Buy” and an average target price of $4.21.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Stock Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related stocks with our FREE daily email newsletter.